Trial NCT02749292

View at ClinicalTrials.gov 
Org. Study IDs: 2015P002541

Last trial update was posted on 2023-07-27

MeSH Interventions

Rituximab

MeSH Conditions

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Vasculitis

Other Conditions


Stopping Reasons

Due to the coronavirus disease 2019 (COVID-19) pandemic and the deleterious impact of rituximab on vaccination efficacy, the trial was concluded before reaching the target enrollment of 200.

Limitations And Caveats

The trial has several limitations: It was open-label. it only enrolled patients on continuous B cell depletion for a minimum of 2 years it took place in a single center.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID